49
52
DAFTAR PUSTAKA
1. Birrer M. Ovarian Cancer: Targeting the Untargetable. American Society of Clinical Oncology Educational Book. 2014;34:13-15.
2. Sahil F.M. Penatalaksanaan Kanker Ovarium pada Wanita Usia Mudan dengan Mempertahankan Fungsi Reproduksi. [Internet]. 1st ed. Medan: Repository USU; 2007 [cited 17 April 2016]. Available from: http://www.repository.usu.ac.id
3. Badan Registrasi Kanker. Kanker di Indonesia tahun 2006 Data Histopatologik. Jakarta: Yayasan Kanker Indonesia; 2006.
4. Coleman R.L., Gerhenson D.M. Neoplastic Disease of The Ovary, in: Katz V.L., Lentz G.M., Lobo R.A., Gerhenson D.M. Comprehensive Gynecology. 5th ed. Philadelphia: Mosby Elsevier. 2007.
5. World Health Organization. WHO Classification of Tumours of Female Reproductive Organ. 4th ed. World Health Organization; 2014.
6. Berek J.S., Natarajan S. Ovarian and Fallopian Tube Cancer, in: Berek $ Novak’s Gynecology. 14th ed. California: Lippincot William & Wilkins. 2007. p: 1457-1531.
7. Copeland L.J. Epithelial Ovarian Cancer, in : Clinical Gynecologic Oncology. 7th ed. Mosby Elsevier inc. 2007. p: 317-371.
8. Fujin C., Zhongli C., Minshan C., Yingbo C., Zhongping C., Nianji C., et al.,editors. Buku Ajar Onkologi Klinis. Edisi 2. Jakarta: Badan Penerbit FK UI; 2013.
9. Gupta, D. And Lis, C.G. Role of CA-125 in predicting ovarian cancer in general population. Past practice & Research Clinical Obstetrics and Gynaecology 26, 2012: 243-256.
10.Sturgeon C, Diamandis E. Use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancer. The American Association for clinical biochemistry. 2009. Hal.51-60
11.Prawirohardjo S., editors. Ilmu Kandungan: Kanker Ganas Alat Genital. Edisi 3. Jakarta: Tridasa Printer; 2011. p. 307-314
48
49
52
12.Eroschenko VP. Atlas Histologi diFiore: Sistem Reproduksi Wanita. Edisi 11. Jakarta: Penerbit Buku Kedokteran EGC; 2008. p.455-462.
13.Widayati P., Ariyanto A., Lestari W. Produksi KIT Immunoradiometricassay (IRMA) CA-125 untuk Deteksi Dini Kanker Ovarium. April 2011.
14.Aziz M.F., et al. Buku Acuan Nasional Onkologi Ginecologi. Edisi 6. Jakarta: Yayasan Bina Pustaka Sarwono Prawirohardjo FKUI; 2006. p.468-527.
15.Bintang A.P., Maria. Profil Penderita Tumor Ganas Ovarium di Rumah Sakit H.Adam Malik Medan pada tahun 2012.[internet].1st ed.Medan: Repository USU; 2014 [cited 17 April 2016]Available from: http://www.repository.usu.ac.id
16.Robbins., Kumar., Abbas., Aster.. Buku Ajar Patologi. Edisi 9. Jakarta: Elsevier; 2015.
17.Nucci M.R., Oliva E., editors. Gynecologic Pathology: Surface Epithelial Stromal Tumors of The Ovary. Boston: Elsevier churcchill livingstone; 2009.
18.DoveMed [Internet]. DoveMed. 2015 [cited 17 April 2016]. Available from: http://www.dovemed.com
19.Agarwal, P. and Kehoe, S. Serum tumour marker in gynaecological cancers. Maturitas 67, 2010: 46-53.
20.Rancourt, C., Matte, I., Lane, D., Piche, A. The role of MUC16 mucin (CA125) in the pathogenesis of ovarian cancer. Ovarian Cancer- Basic Science Perspective, available from : www.intechopen.com. Diunduh pada
2 Februari 2014.
21.Scholler, N. and Urban, N. 2007. CA125 in ovarian cancer. Biomark Med, 2007: December; 1(4): 513-523.
22.Gentry-Maharaj, A. and Menon, U. Screening for ovarian cancer in general population. Best Practice & Research Clinical Obstetrics and Gynaecology 26, 2012: 243-256.
49
52
23.Das, P.M. and Bast, R.C. Early Detection of ovarian cancer. Biomark Med, 2008: June; 2(3): 291-303.
24.Foundation for Women’s Cancer [internet]. Ovarian Cancer. Foundation for Women’s Cancer. 2016. [cited 17 April 2016]. Available from: www.foundationforwomenscancer.org
25.E L Moss, J Hollingworth, T M Reynolds . The role of CA125 in clinical practice, Available from URL : jcp.bmj.com Published by : group.bmj.com
26.Ferdyansyah T., Sofian A., Fatmawati. Hubungan Tumor Marker CA-125 dengan Sifat dan Tipe Sel Tumor Ovarium di RSUD Arifin Achmad Pekanbaru. Pekanbaru; April 2014.
27.C Ben, T Drik, B Tom, T Antonia, H Caroline, D Ekaterini, J Davor, N Patrick, et al. Discrimination between benign and malignant by specialist ultrasound examination versus serum CA-125.Journal National cancer institute. 2007
28.FIGO, Annual report on the Result of Treatment I Gynecological, J Epid Biostat, 1998.
29.Regarding Ovarian Cancer, advanced obgyn associated obstetric gynecology & infertilty. Available from URL : http://www.advanced obgynassociates.com/ovarian-cancer.htm
30.Women Should be offered a blood test for ovarian cancer, NICE Guidance. United Kingdom’s National Institute for health & Clinical Excellence 2011.
31.Barliana., Faroek Hoesin., Dyah Fauziah. Ekspresi Protein HER-2/neu pada Berbagai Tipe Karsinoma Ovarium. Januari 2014.
32.Andi F.F., Zulkifly A., Syamsiar S.R. Faktor Risiko Kanker Ovarium di RSUP Wahidin Sudirohusodo Makassar. 2014.
33.Badan Penelitian dan Pengembangan Indonesia. Prevalensi Tumor dan Beberapa Faktor yang Mempengaruhinya di Indonesia. Oktober 2011.
50
49
52
34.Pemaron I.B.U. Modifikasi Indeks Risiko Keganasan Sebagai Modalitas Diagnostik Preoperatif Untuk Memprediksi Keganasan Tumor Ovarium : Suatu Uji Diagnostik. 2013.
51
